Yipinhong Pharmaceutical Co Ltd Class A (SHE:300723) — Market Cap & Net Worth
Market Cap & Net Worth: Yipinhong Pharmaceutical Co Ltd Class A (300723)
Yipinhong Pharmaceutical Co Ltd Class A (SHE:300723) has a market capitalization of $2.25 Billion (CN¥15.36 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #5781 globally and #1080 in its home market, demonstrating a -2.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yipinhong Pharmaceutical Co Ltd Class A's stock price CN¥34.00 by its total outstanding shares 451692766 (451.69 Million). Also see how large is Yipinhong Pharmaceutical Co Ltd Class A's balance sheet for a full breakdown of the balance sheet.
Yipinhong Pharmaceutical Co Ltd Class A Market Cap History: 2017 to 2026
Yipinhong Pharmaceutical Co Ltd Class A's market capitalization history from 2017 to 2026. Data shows growth from $843.63 Million to $2.25 Billion (16.62% CAGR). Also see Yipinhong Pharmaceutical Co Ltd Class A operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Yipinhong Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Yipinhong Pharmaceutical Co Ltd Class A for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.38x
Yipinhong Pharmaceutical Co Ltd Class A's market cap is 2.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $843.63 Million | $1.38 Billion | $156.70 Million | 0.61x | 5.38x |
| 2018 | $629.59 Million | $1.43 Billion | $208.22 Million | 0.44x | 3.02x |
| 2019 | $908.89 Million | $1.64 Billion | $143.69 Million | 0.56x | 6.33x |
| 2020 | $956.84 Million | $1.68 Billion | $225.61 Million | 0.57x | 4.24x |
| 2021 | $1.55 Billion | $2.20 Billion | $306.92 Million | 0.70x | 5.04x |
| 2022 | $1.50 Billion | $2.28 Billion | $290.68 Million | 0.66x | 5.16x |
| 2023 | $1.95 Billion | $2.50 Billion | $184.61 Million | 0.78x | 10.58x |
| 2024 | $1.13 Billion | $1.45 Billion | -$540.04 Million | 0.78x | N/A |
| 2025 | $2.22 Billion | $932.27 Million | -$337.79 Million | 2.38x | N/A |
Competitor Companies of 300723 by Market Capitalization
Companies near Yipinhong Pharmaceutical Co Ltd Class A in the global market cap rankings as of September 19, 2026. Review Yipinhong Pharmaceutical Co Ltd Class A tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Yipinhong Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Yipinhong Pharmaceutical Co Ltd Class A Historical Marketcap From 2017 to 2026
Between 2017 and today, Yipinhong Pharmaceutical Co Ltd Class A's market cap moved from $843.63 Million to $ 2.25 Billion, with a yearly change of 16.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.25 Billion | +1.34% |
| 2025 | CN¥2.22 Billion | +96.66% |
| 2024 | CN¥1.13 Billion | -42.27% |
| 2023 | CN¥1.95 Billion | +30.21% |
| 2022 | CN¥1.50 Billion | -3.00% |
| 2021 | CN¥1.55 Billion | +61.63% |
| 2020 | CN¥956.84 Million | +5.28% |
| 2019 | CN¥908.89 Million | +44.36% |
| 2018 | CN¥629.59 Million | -25.37% |
| 2017 | CN¥843.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Yipinhong Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.25 Billion USD |
| MoneyControl | $2.25 Billion USD |
| MarketWatch | $2.25 Billion USD |
| marketcap.company | $2.25 Billion USD |
| Reuters | $2.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more